Please assess the completion status of the following clinical trial:

Trial Title: Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with confirmed HIV infection~* Age ≥ 18 years~* Written informed consent~* Male patient or non-pregnant, non-lactating female~* No previous treatment with any antiretroviral drugs~* HIV-1 RNA \> 1000 copies/ml~* Indication to start an antiretroviral treatment as long as subject has also a CD4 cell count ≤ 500/mm3 either at screening or on a sample taken within 3 months before screening~* No major IAS-USA mutations on genotypic testing at the screening visit or on any historical genotype, if available~Non-inclusion Criteria:~* Woman without effective contraception method (recommended contraception during the trial is mechanical + a second method other than an oral contraceptive)~* Pregnant or breastfeeding woman~* Woman expecting to conceive during the study~* HIV-2 co-infection~* Creatinine clearance \< 60 ml/mn (Cockcroft \& Gault equation), alkaline phosphatase, ASAT, or ALAT ≥ 5 ULN~* Patient with significant impairment of hepatic function, defined as serum albumin \< 2.8 g/dl or INR \> 1.7 or presence of ascites, in the absence of another explanation for the abnormal finding~* CD4 \> 500/mm3 at screening, except in case of symptomatic HIV disease (defined by conditions qualifying for CDC category B or C) or CD4 ≤ 500/mm3 on a sample taken within 3 months before screening.~* Any major IAS-USA mutation conferring resistance to one or more of reverse transcriptase or protease inhibitors on genotypic testing at screening~* Mycobacteriosis under treatment~* Malignancy requiring chemotherapy or radiotherapy~* Positive HBs Ag~* HCV infection for which specific treatment is ongoing or planned during the first year on trial treatment~* Known hypersensitivity to one of the trial drugs or its excipients~* Contraindicated concomitant treatment~* Anticipated non-compliance with the protocol~* Participation in another clinical trial with an on-going exclusion period at screening~* Subject under legal guardianship or incapacitation~* Subject, who in the opinion of the investigator, is unable to complete the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darunavir/r + tenofovir/emtricitabine (Type: ACTIVE_COMPARATOR): None
- darunavir/r + raltegravir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).